These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26660898)

  • 1. Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection.
    Ito F; Ohno Y; Toyoshi S; Kaito D; Koumei Y; Endo J; Kamamiya F; Mori H; Mori M; Morishita M; Funaguchi N; Minatoguchi S
    Ther Adv Respir Dis; 2016 Feb; 10(1):34-42. PubMed ID: 26660898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y; Morita K; Takeda H; Kishino S; Okumura S; Fujiuchi S
    Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of intravenous moxifloxacin 400 mg once-daily dosage in infected patients.
    Zhu L; Wang N; Yang W; Zhang Y; Zhao X; Ji S
    J Infect Chemother; 2014 Oct; 20(10):621-6. PubMed ID: 25000831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.
    Wicha SG; Haak T; Zink K; Kees F; Kloft C; Kees MG
    J Clin Pharmacol; 2015 Jun; 55(6):639-46. PubMed ID: 25600294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
    Niki Y; Yoshida K; Miyashita N; Oka M; Hara H; Kishimoto M; Okimoto N; Kawanishi M; Uno M; Kamao T; Yoneyama H; Nakamura J; Kimura M; Watanabe M; Tanimukai T; Moriya O; Matsushima T
    J Infect Chemother; 2008 Aug; 14(4):296-304. PubMed ID: 18709533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and Tissue Disposition of Moxifloxacin in Japanese Quail ( Coturnix japonica ).
    Goudah A; Hasabelnaby S
    J Avian Med Surg; 2016 Jun; 30(2):103-10. PubMed ID: 27315376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
    Kontou P; Manika K; Chatzika K; Papaioannou M; Sionidou M; Pitsiou G; Kioumis I
    Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis.
    Pea F; Pavan F; Lugatti E; Dolcet F; Talmassons G; Screm MC; Furlanut M
    Clin Pharmacokinet; 2006; 45(3):287-95. PubMed ID: 16509760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections.
    Kohno S; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Fujita J; Tanigawara Y
    J Infect Chemother; 2013 Jun; 19(3):486-94. PubMed ID: 23525983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion.
    Chatzika K; Manika K; Kontou P; Pitsiou G; Papakosta D; Zarogoulidis K; Kioumis I
    Antimicrob Agents Chemother; 2014; 58(3):1315-9. PubMed ID: 24323477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of intravenous moxifloxacin in the cerebrospinal fluid of a patient with central nervous system shunt infection.
    Zhang B; Huang X; Fan H; Zeng X; Mei D; Fu Q
    Diagn Microbiol Infect Dis; 2016 Mar; 84(3):249-51. PubMed ID: 26746981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
    Tanigawara Y; Kaku M; Totsuka K; Tsuge H; Saito A
    J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of poor compliance with levofloxacin and moxifloxacin on respiratory tract infection antimicrobial efficacy: a pharmacokinetic/pharmacodynamic simulation study.
    Carral N; Lukas JC; Oteo I; Suarez E
    Int J Antimicrob Agents; 2015 Jan; 45(1):79-83. PubMed ID: 25450804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia.
    Tokimatsu I; Shigemura K; Kotaki T; Yoshikawa H; Yamamichi F; Tomo T; Arakawa S; Fujisawa M; Kadota JI
    Intern Med; 2017; 56(11):1315-1319. PubMed ID: 28566592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma disposition and tissue residue of Moxifloxacin in Japanese quails (Coturnix japonica) following different routes of administration.
    Goudah A; Hasabelnaby S
    Br Poult Sci; 2014; 55(5):693-8. PubMed ID: 25185118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
    Salem AH; Noreddin AM
    J Chemother; 2014 Apr; 26(2):80-5. PubMed ID: 24090676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta).
    Marín P; Lai OR; Laricchiuta P; Marzano G; Di Bello A; Cárceles CM; Crescenzo G
    Res Vet Sci; 2009 Oct; 87(2):284-6. PubMed ID: 19375138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.